In a nod to the First Amendment, the Federal Drug Administration is proposing new guidelines allowing pharmaceutical companies to downplay official safety warnings in sales pitches about drugs. The industry has long argued that it has a free speech right to publish information about their products without government restrictions. (The Washington Post, March 11, 2015, by Peter Whoriskey)
In a press release, Public Citizen argued that giving the industry freedom to contradict FDA warnings would damage safety shields for patients in the interests of industry profits. (noodls, March 11, 2015)